Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.
Acquired thrombotic thrombocytopenic purpura is primarily caused by the deficiency of plasma ADAMTS13 activity resulting from autoantibodies against ADAMTS13. However, ADAMTS13 deficiency alone is often not sufficient to cause acute thrombotic thrombocytopenic purpura. Infections or systemic inflammation may precede acute bursts of the disease, but the underlying mechanisms are not fully understood. Herein, 52 patients with acquired autoimmune thrombotic thrombocytopenic purpura and 30 blood donor controls were recruited for the study. The plasma levels of human neutrophil peptides 1-3 and complement activation fragments (i.e. Bb, iC3b, C4d, and sC5b-9) were determined by enzyme-linked immunosorbent assays. Univariate analyses were performed to determine the correlation between each biomarker and clinical outcomes. We found that the plasma levels of human neutrophil peptides 1-3 and Bb in patients with acute thrombotic thrombocytopenic purpura were significantly higher than those in the control (P<0.0001). The plasma levels of HNP1-3 correlated with the levels of plasma complement fragment Bb (rho=0.48, P=0.0004) and serum lactate dehydrogenase (rho=0.28, P=0.04); in addition, the plasma levels of Bb correlated with iC3b (rho=0.55, P<0.0001), sC5b-9 (rho=0.63, P<0.0001), serum creatinine (rho=0.42, p=0.0011), and lactate dehydrogenase (rho=0.40, P=0.0034), respectively. Moreover, the plasma levels of iC3b and sC5b-9 were correlated (rho=0.72, P<0.0001), despite no statistically significant difference of the two markers between thrombotic thrombocytopenic purpura patients and the control. We conclude that innate immunity, i.e. neutrophil and complement activation via the alternative pathway, may play a role in the pathogenesis of acute autoimmune thrombotic thrombocytopenic purpura, and a therapy targeted at these pathways may be considered in a subset of these patients.
Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, AL, USA.
Wenjing
W
Cao
Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, AL, USA.
Huy P
HP
Pham
Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, AL, USA.
Lance A
LA
Williams
Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, AL, USA.
Jenny
J
McDaniel
Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, AL, USA.
Rance C
RC
Siniard
Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, AL, USA.
Robin G
RG
Lorenz
Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, AL, USA.
Marisa B
MB
Marques
Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, AL, USA xzheng@uabmc.edu.
X Long
XL
Zheng
D000328:Adult; D015415:Biomarkers / Q000097:blood; D011415:Complement Factor B / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007113:Immunity, Innate; D008297:Male; D011697:Purpura, Thrombotic Thrombocytopenic / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D023084:alpha-Defensins / Q000097:blood*
D015415:Biomarkers; D023084:alpha-Defensins; C406413:human neutrophil peptide 1; C406416:human neutrophil peptide 2; C406427:human neutrophil peptide 3; D011415:Complement Factor B
Nat Rev Nephrol. 2012 Nov;8(11):622-33
22986360
J Atheroscler Thromb. 2012;19(4):357-68
22186100
Transfus Apher Sci. 2013 Jun;48(3):353-8
23602056
J Clin Apher. 1998;13(1):16-9
9590492
Blood. 2013 Sep 19;122(12 ):2023-9; quiz 2142
23838348
J Vasc Surg. 2006 Feb;43(2):357-63
16476615
N Engl J Med. 1991 Aug 8;325(6):398-403
2062331
Eur Cytokine Netw. 2000 Jun;11(2):257-66
10903805
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9620-5
26203127
J Thromb Haemost. 2011 Jul;9 Suppl 1:283-301
21781265
J Exp Med. 2006 Mar 20;203(3):767-76
16533881
J Biol Chem. 1996 Jul 26;271(30):17650-5
8663495
Arch Pathol Lab Med. 2003 Jul;127(7):834-9
12823037
Blood. 2016 Jul 7;128(1):110-9
27207796
Ann Intern Med. 2003 Jan 21;138(2):105-8
12529092
Arterioscler Thromb Vasc Biol. 2014 May;34(5):996-1001
24504734
Thromb Haemost. 2011 Nov;106(5):947-58
21901237
Thromb Res. 2014 Apr;133(4):616-21
24548690
Curr Opin Hematol. 2014 Jan;21(1):37-42
24275690
Br J Haematol. 2005 Apr;129(1):93-100
15801961
Blood. 2012 Aug 9;120(6):1157-64
22611154
Thromb Haemost. 2005 Mar;93(3):443-52
15735793
J Lab Clin Med. 1993 Aug;122(2):202-7
8340706
Blood. 2004 Jun 1;103(11):4043-9
14982878
J Vasc Surg. 1997 May;25(5):816-27; discussion 828
9152309
Br J Haematol. 2014 Mar;164(6):858-66
24372446
Immunology. 2009 May;127(1):116-22
19191901
Blood. 2013 May 9;121(19):4012-3
23660864
Blood. 2012 Mar 8;119(10 ):2385-91
22123843
Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H1817-24
18805897
BMC Nephrol. 2013 Jul 20;14:156
23870247
Blood. 2010 Nov 18;116(20):4060-9
20686117
N Engl J Med. 1982 Dec 2;307(23):1432-5
6813740
Mol Immunol. 2007 Jul;44(14):3608-14
17448537
Br J Haematol. 2001 Jun;113(3):649-51
11380451
J Thromb Haemost. 2005 Mar;3(3):562-70
15748247
Blood. 2009 Aug 20;114(8):1666-74
19541819
J Thromb Haemost. 2012 Apr;10(4):647-61
22268819
J Thromb Haemost. 2012 May;10 (5):791-8
22372946
Annu Rev Med. 2015 ;66:211-25
25587650
Chin Med J (Engl). 2013;126(10):1913-7
23673109
Hematol Oncol Clin North Am. 2007 Aug;21(4):609-32, v
17666281
J Thromb Haemost. 2013 Oct;11(10 ):1925-7
23927533
Blood. 2012 Jul 12;120(2):440-8
22529288
Blood. 2002 Dec 1;100(12 ):4033-9
12393397
PLoS One. 2013;8(3):e59372
23555663